RSV Vaccination Delivers Significant Protection for Older Adults

The JAMA Network Open recently published results from an Original Investigation demonstrating respiratory syncytial virus (RSV) vaccine effectiveness in older adults of 90% for RSV–related hospitalization and emergency department visits.

This study provides real-world VE data from the 2023-24 RSV season.

Published on December 13, 2024, these researchers wrote, 'These data (based on data from Kaiser Permanente of Southern California) supports the use of this vaccine (ABRYSVO™) in older adults.'

Pfizer Inc.'s ABRYSVO™ RSVpreF bivalent prefusion F subunit vaccine is a U.S. Food and Drug Administration-approved vaccine.